CELL THERAPY 360
LIVE

Serial Number

88347099

Owner

Celgene Corporation

Attorney

Marilyn F. Kelly

Filing Date

Mar 19, 2019

Add to watchlist:

No watchlists yet
View on USPTO

CELL THERAPY 360 Trademark

Serial Number: 88347099 • Registration: 5889482

CELL THERAPY 360 is a trademark filed by Celgene Corporation on March 19, 2019. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 36 (Insurance & Financial), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services). The application is currently registered and active.

Owner Contact Info

Celgene Corporation (883 trademarks)

7 Powder Horn Drive
Warren, NJ 07059

Entity Type: 03

Trademark Details

Filing Date

March 19, 2019

Registration Date

October 22, 2019

Published for Opposition

August 6, 2019

Goods & Services

[Downloadable computer software enabling patients to manage and access data relating to the treatment of cancer and immunological disorders; downloadable computer application software for use on mobile phones and mobile electronic devices for use in connection with providing medical information in the field of cancer and immunological disorders; downloadable electronic publications, namely, newsletters and articles featuring medical information in the field of cancer and immunological disorders; downloadable videos featuring medical information in the field of cancer and immunological disorders; downloadable computer software for application and database integration]

Providing medical information; providing health information in the field of oncology and immunological disorders; providing a web site featuring medical information; providing a web site featuring health information in the field of oncology and immunological disorders; providing medical information, consultancy and advisory services; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals

[Providing patient advocate services in the field of the treatment of diseases and disorders]

[Pharmaceutical preparations, namely, preparations for use in the treatment of cancer and tumors; pharmaceutical and biological preparations for immunotherapy, including T Cell therapy]

[Software as a Service (SaaS) services featuring software that allows patients to manage and access data relating to the treatment of cancer and immunological disorders; application service provider (ASP) featuring software for medical affair management and information exchange; providing a website featuring non-downloadable software for medical affair management and information exchange; providing an on-line computer database featuring medical and scientific research information in the field of cancer and immunological disorders that allows for input and collection of scientific and research data and information; medical and scientific research liaison services, namely, consulting in the field of scientific research pertaining to clinical trials in the fields of health care, medicine, pharmacology and biotechnology; scientific research consultation pertaining to clinical trials; providing medical and scientific research information in the field of clinical trials]

[Financial administration of patient reimbursement programs; financial administration of medication reimbursement programs and services]

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Nov 20, 2025 NA85
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Nov 20, 2025 C15P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 20, 2025 APRE
TEAS SECTION 8 & 15 RECEIVED
Aug 4, 2025 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Oct 22, 2024 REM1
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 9, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 9, 2022 TCCA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Dec 9, 2022 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 9, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 9, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Dec 9, 2022 COAR
REGISTERED-PRINCIPAL REGISTER
Oct 22, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 6, 2019 NPUB
PUBLISHED FOR OPPOSITION
Aug 6, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 17, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 28, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 28, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 28, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 28, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 28, 2019 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 24, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 24, 2019 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jun 21, 2019 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
May 1, 2019 GNS3
LETTER OF SUSPENSION E-MAILED
May 1, 2019 GNSL
SUSPENSION LETTER WRITTEN
May 1, 2019 CNSL
EXAMINER'S AMENDMENT ENTERED
May 1, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 1, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
May 1, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 1, 2019 CNEA
ASSIGNED TO EXAMINER
Apr 28, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 6, 2019 NWOS
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Mar 30, 2019 AMPX
ASSIGNED TO LIE
Mar 28, 2019 ALIE
TEAS VOLUNTARY AMENDMENT RECEIVED
Mar 22, 2019 PARI
NEW APPLICATION ENTERED
Mar 22, 2019 NWAP